Choice Of Regulatory Pathway Is Key Inflection Point In US Drug Reviews
This article was originally published in SRA
Executive Summary
The proliferation of regulatory pathways gives the US Food and Drug Administration a powerful way to set priorities and shape drug development, according to an analysis by Scrip Regulatory Affairs' sister publication The Pink Sheet.